Market Cap 186.03M
Revenue (ttm) 0.00
Net Income (ttm) -90.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,455,744
Avg Vol 4,323,218
Day's Range N/A - N/A
Shares Out 217.00M
Stochastic %K 8%
Beta 2.77
Analysts Strong Sell
Price Target $9.00

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacet...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 825 6990
Address:
171 Oyster Point Boulevard, Suite 500, South San Francisco, United States
Spinaroonie
Spinaroonie May. 19 at 6:53 PM
$TNYA down to 77 like i said
1 · Reply
BIOVIC
BIOVIC May. 19 at 5:30 PM
$TNYA defended $0.75, reclaimed $0.78, broke $0.80. Volume above 90-day median. 25% short float into a Cohort 2 readout window opening any day. The setup is doing what the setup was supposed to do. Watching the close.
0 · Reply
Abzino88
Abzino88 May. 19 at 4:24 PM
$TNYA uptrend still holds … needs to close above 0.78 - if it doesn't I'm still very bullish with this, why? because its a highly volatile small biotech company that has a lot of potential!
0 · Reply
Raumerica
Raumerica May. 19 at 4:03 PM
$TNYA will be Nasdaq compliant soon.
1 · Reply
Yung_Ball3R
Yung_Ball3R May. 19 at 4:00 PM
$TNYA Averaged down again, holding 19,000 shares at .85 average
1 · Reply
THE_MADMAN
THE_MADMAN May. 19 at 3:37 PM
$TNYA it's up 2 cents relax
0 · Reply
Damage111
Damage111 May. 19 at 3:04 PM
0 · Reply
BIOVIC
BIOVIC May. 19 at 2:40 PM
$TNYA 🔥🔥🔥🔥🔥🔥🔥 Shorts jajajajajajajjaajaja
1 · Reply
BIOVIC
BIOVIC May. 19 at 2:37 PM
$TNYA bid defended $0.75, reclaimed $0.78 on the bounce. Cohort 2 data guided before June 30 and webcast announcements typically drop 1-3 weeks ahead — that window is open now. The PR itself is the catalyst. Shorts get a deadline they can’t dodge.
0 · Reply
GhostTrader11
GhostTrader11 May. 19 at 2:18 PM
$TNYA Know the macro...
0 · Reply
Latest News on TNYA
Tenaya Therapeutics Transcript: Study update

May 15, 2026, 10:30 AM EDT - 4 days ago

Tenaya Therapeutics Transcript: Study update


Tenaya Therapeutics Press release: Study update

May 15, 2026, 10:30 AM EDT - 4 days ago

Tenaya Therapeutics Press release: Study update


Tenaya Therapeutics Slides: Study update

May 15, 2026, 10:30 AM EDT - 4 days ago

Tenaya Therapeutics Slides: Study update


Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)

2026-05-07T00:34:31.000Z - 12 days ago

Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)


Tenaya Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 12 days ago

Tenaya Therapeutics Earnings release: Q1 2026


Tenaya Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 12 days ago

Tenaya Therapeutics Quarterly report: Q1 2026


Tenaya Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 weeks ago

Tenaya Therapeutics Proxy statement: Proxy filing


Tenaya Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 weeks ago

Tenaya Therapeutics Proxy statement: Proxy filing


Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

2026-03-11T20:27:09.000Z - 2 months ago

Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)


Tenaya Therapeutics Annual report: Q4 2025

Mar 11, 2026, 4:00 PM EDT - 2 months ago

Tenaya Therapeutics Annual report: Q4 2025


Tenaya Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 4:00 PM EDT - 2 months ago

Tenaya Therapeutics Earnings release: Q4 2025


Tenaya Therapeutics presents preclinical data evaluating TN-301

2026-03-09T12:41:56.000Z - 2 months ago

Tenaya Therapeutics presents preclinical data evaluating TN-301


Tenaya Therapeutics announces 2026 strategic priorities

2026-01-09T13:41:19.000Z - 4 months ago

Tenaya Therapeutics announces 2026 strategic priorities


Tenaya Therapeutics 50M share Spot Secondary priced at $1.20

2025-12-12T07:00:10.000Z - 5 months ago

Tenaya Therapeutics 50M share Spot Secondary priced at $1.20


Tenaya Therapeutics Announces Pricing of Public Offering

Dec 12, 2025, 12:16 AM EST - 5 months ago

Tenaya Therapeutics Announces Pricing of Public Offering


Tenaya Therapeutics Transcript: Study Result

Dec 11, 2025, 5:00 PM EST - 5 months ago

Tenaya Therapeutics Transcript: Study Result


Tenaya Therapeutics Press release: Study Result

Dec 11, 2025, 5:00 PM EST - 5 months ago

Tenaya Therapeutics Press release: Study Result


Tenaya Therapeutics Slides: Study Result

Dec 11, 2025, 5:00 PM EST - 5 months ago

Tenaya Therapeutics Slides: Study Result


Tenaya Therapeutics  files to sell common stock, no amount given

2025-12-11T21:20:52.000Z - 5 months ago

Tenaya Therapeutics files to sell common stock, no amount given


Tenaya Therapeutics Announces Proposed Public Offering

Dec 11, 2025, 4:02 PM EST - 5 months ago

Tenaya Therapeutics Announces Proposed Public Offering


Tenaya Therapeutics Slides: Corporate Presentation

Dec 11, 2025, 7:00 AM EST - 5 months ago

Tenaya Therapeutics Slides: Corporate Presentation


Tenaya Therapeutics Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 6 months ago

Tenaya Therapeutics Transcript: Status Update


Tenaya Therapeutics Press release: Status Update

Nov 10, 2025, 8:00 AM EST - 6 months ago

Tenaya Therapeutics Press release: Status Update


Tenaya Therapeutics Slides: Status Update

Nov 10, 2025, 8:00 AM EST - 6 months ago

Tenaya Therapeutics Slides: Status Update


Tenaya Therapeutics reports Q3 EPS (12c), consensus (15c)

2025-11-10T12:06:39.000Z - 6 months ago

Tenaya Therapeutics reports Q3 EPS (12c), consensus (15c)


Tenaya Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Tenaya Therapeutics Earnings release: Q3 2025


Tenaya Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Tenaya Therapeutics Quarterly report: Q3 2025


Tenaya Therapeutics management to meet with Piper Sandler

2025-10-21T20:45:22.000Z - 7 months ago

Tenaya Therapeutics management to meet with Piper Sandler


Tenaya Therapeutics Slides: Corporate Presentation

Sep 9, 2025, 7:00 AM EDT - 9 months ago

Tenaya Therapeutics Slides: Corporate Presentation


Tenaya Therapeutics Transcript: KOL Event

Aug 26, 2025, 11:30 AM EDT - 9 months ago

Tenaya Therapeutics Transcript: KOL Event


Tenaya Therapeutics Slides: Corporate Presentation

Aug 13, 2025, 4:00 PM EDT - 9 months ago

Tenaya Therapeutics Slides: Corporate Presentation


Tenaya Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Tenaya Therapeutics Quarterly report: Q2 2025


Tenaya Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Tenaya Therapeutics Earnings release: Q2 2025


Tenaya Therapeutics Earnings release: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q1 2025


Tenaya Therapeutics Quarterly report: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Quarterly report: Q1 2025


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Annual report: Q4 2024

Mar 10, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Annual report: Q4 2024


Tenaya Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q4 2024


Tenaya Therapeutics Transcript: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Transcript: Study Update


Tenaya Therapeutics Press release: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Press release: Study Update


Tenaya Therapeutics Slides: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Slides: Study Update


Tenaya Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Tenaya Therapeutics Quarterly report: Q3 2024


Tenaya Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Tenaya Therapeutics Earnings release: Q3 2024


Tenaya Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Quarterly report: Q2 2024


Tenaya Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q2 2024


Tenaya Therapeutics Announces Research Leadership Updates

Jun 27, 2024, 5:00 PM EDT - 2 years ago

Tenaya Therapeutics Announces Research Leadership Updates


Tenaya Therapeutics Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Quarterly report: Q1 2024


Tenaya Therapeutics Earnings release: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q1 2024


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Earnings release: Q4 2023

Mar 18, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q4 2023


Tenaya Therapeutics Annual report: Q4 2023

Mar 18, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Annual report: Q4 2023


Tenaya Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Tenaya Therapeutics Quarterly report: Q3 2023


Tenaya Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Tenaya Therapeutics Earnings release: Q3 2023


Tenaya Therapeutics Slides: Corporate Presentation

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Tenaya Therapeutics Slides: Corporate Presentation


Spinaroonie
Spinaroonie May. 19 at 6:53 PM
$TNYA down to 77 like i said
1 · Reply
BIOVIC
BIOVIC May. 19 at 5:30 PM
$TNYA defended $0.75, reclaimed $0.78, broke $0.80. Volume above 90-day median. 25% short float into a Cohort 2 readout window opening any day. The setup is doing what the setup was supposed to do. Watching the close.
0 · Reply
Abzino88
Abzino88 May. 19 at 4:24 PM
$TNYA uptrend still holds … needs to close above 0.78 - if it doesn't I'm still very bullish with this, why? because its a highly volatile small biotech company that has a lot of potential!
0 · Reply
Raumerica
Raumerica May. 19 at 4:03 PM
$TNYA will be Nasdaq compliant soon.
1 · Reply
Yung_Ball3R
Yung_Ball3R May. 19 at 4:00 PM
$TNYA Averaged down again, holding 19,000 shares at .85 average
1 · Reply
THE_MADMAN
THE_MADMAN May. 19 at 3:37 PM
$TNYA it's up 2 cents relax
0 · Reply
Damage111
Damage111 May. 19 at 3:04 PM
0 · Reply
BIOVIC
BIOVIC May. 19 at 2:40 PM
$TNYA 🔥🔥🔥🔥🔥🔥🔥 Shorts jajajajajajajjaajaja
1 · Reply
BIOVIC
BIOVIC May. 19 at 2:37 PM
$TNYA bid defended $0.75, reclaimed $0.78 on the bounce. Cohort 2 data guided before June 30 and webcast announcements typically drop 1-3 weeks ahead — that window is open now. The PR itself is the catalyst. Shorts get a deadline they can’t dodge.
0 · Reply
GhostTrader11
GhostTrader11 May. 19 at 2:18 PM
$TNYA Know the macro...
0 · Reply
Raumerica
Raumerica May. 19 at 2:15 PM
$AKBA $TNYA Spinaroonie is Patience 4200. Block this pathetic FUDster!
0 · Reply
Patience4200
Patience4200 May. 19 at 2:14 PM
$TNYA $AKBA has far more potential than this Trainwreck.
3 · Reply
Raumerica
Raumerica May. 19 at 2:13 PM
$TNYA And soon when it is $2.50+ the $1.50 warrants will be converted and it will be another cool $75 million in TNYA’s company coffers!
1 · Reply
Raumerica
Raumerica May. 19 at 2:10 PM
$TNYA Block this pathetic clown. I am sure institutions are going to buy 50 million (23% of the company) @$1.20 in December and then RS in May. This is Spinaroonie the board joke’s argument! Block him. I will handle his BS, don’t worry!
0 · Reply
AutisticRetardo
AutisticRetardo May. 19 at 2:05 PM
$TNYA Series B warrants (.70) expire on June 30. That's another 24.5m in the bank for Tenaya. Just sit tight and ignore the trolls. Hedge funds are trying to shake you out for liquidity
0 · Reply
Spinaroonie
Spinaroonie May. 19 at 1:59 PM
$TNYA wow tanking like the company wants RS SOON
0 · Reply
Raumerica
Raumerica May. 19 at 1:35 PM
$TNYA Yeah everybody is really scared : 35 million were bought at or above a dollar over 3 days a week ago. Only 22 million shares to over the last 5 trading sessions to take it down to 76 cents right now. Yawn… Block this pathetic FAKE FUDSTER!
2 · Reply
Spinaroonie
Spinaroonie May. 19 at 1:11 PM
$TNYA manipulation at its finest, CEO a crook, SELL
1 · Reply
BIOVIC
BIOVIC May. 19 at 11:22 AM
$TNYA Cohort 2 data guided before June 30. Companies typically announce the webcast date 1-3 weeks ahead. That puts the announcement window open right now. The PR itself is a catalyst — it de-risks timing and forces shorts to mark the calendar.
0 · Reply
Raumerica
Raumerica May. 19 at 11:00 AM
$TNYA TNYA will file and receive another 180 day extension with no problem, if necessary. Doubt they will need to however.
0 · Reply
wins2love
wins2love May. 19 at 10:56 AM
$TNYA the problem with pumping any stock around a specific timeline or event, is it always ends up where we are now. Even if it goes up 25-100%, many sell trying to lock in those profits. The 5 day and 30 day charts show just that. The ONLY questions now are 1) do we fall all the way back to the mid-60’s or can we hold some higher level and 2) does the institutional share percent rebound or continue its small drop from 50% to 47.14% over the last 30 days. That is the exaggerated battle the shorts and longs will be settling over the coming days/weeks. The shorts will be selling a potential RS, which has never happened in the companies history (and is not likely anytime soon). While the longs will point to the relatively secure financial footing established at the end of 2025 and that multiple cohorts are progressing along simultaneous timelines. For my money, the potential upside is still far greater than the downside, but the rollercoaster ride continues nonetheless.
0 · Reply
Matthewznp
Matthewznp May. 19 at 6:53 AM
0 · Reply